In a reverse contrast strategy, Wu et al. (2013) have used SNA lectin to capture sialylated glycoproteins and biotinylated-antibodies to detect clusterin, complement factor H, hemopexin and vitamin D-binding protein to validate the altered levels of the respective glycoproteins in sera of patients with ovarian cancer. This evidence concerns the gene CLU and ovarian cancer.